Evidence map›Paper›PMID 37400396›Full record

ReviewZhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology2023

[Research progress of FAPI PET/CT in the diagnosis of malignant liver tumors].

X Y Zhang, W Han, Z H Lyu, H Y Zhao, P Fu, C J Zhao

Open access · greenAbstract readReviewEnglish Abstract
PubMed Full text at PMC Publisher
In one paragraph

Review in Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 87% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

X Y ZhangDepartment of Nuclear Medicine, The First Clinical Hospital Affiliated to Harbin Medical University, Harbin 150001, China.
W HanDepartment of Nuclear Medicine, The First Clinical Hospital Affiliated to Harbin Medical University, Harbin 150001, China.
Z H LyuDepartment of Nuclear Medicine, The First Clinical Hospital Affiliated to Harbin Medical University, Harbin 150001, China.
H Y ZhaoDepartment of Nuclear Medicine, The First Clinical Hospital Affiliated to Harbin Medical University, Harbin 150001, China.
P FuDepartment of Nuclear Medicine, The First Clinical Hospital Affiliated to Harbin Medical University, Harbin 150001, China.
C J ZhaoDepartment of Nuclear Medicine, The First Clinical Hospital Affiliated to Harbin Medical University, Harbin 150001, China.
Harbin Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Malignant liver tumors have a high incidence and mortality rate. Therefore, it is of great significance to promptly learn about tumor advancement status through relevant examinations for patients' follow-up, diagnosis, and therapy as well as the improvement of the five-year survival rate. The primary lesions and intrahepatic metastases of malignant liver tumors have been better demonstrated in the clinical study with the use of various isotope-labeled fibroblast activating protein inhibitors because of their low uptake in liver tissues and high tumor/background ratio, which provides a new method for early diagnosis, precise staging, and radionuclide therapy. In light of this context, a review of the research progress of fibroblast-activating protein inhibitors for the diagnosis of liver malignant tumors is presented.

Indexed as

Carcinoma, HepatocellularLiver NeoplasmsHumansPositron Emission Tomography Computed Tomography(18)F-deoxyglucoseFibroblast activator protein inhibitorHepatocellular carcinomaIntrahepatic cholangiocarcinomaMetastatic liver cancerPositron emission tomography and computed tomography

Identifiers

PMID37400396
PMCPMC12850677
OpenAlexW4383058817

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.